BridgeBio Pharma to Participate in September Investor Events
28 Agosto 2024 - 6:30AM
BridgeBio Pharma, Inc. (Nasdaq: BBIO) (BridgeBio), a
commercial-stage biopharmaceutical company focused on genetic
diseases, today announced that members of the management team will
participate in the following upcoming investor conferences:
- Morgan Stanley
22nd Annual Global Health Care
Conference, New York, NY: Fireside Conversation on
September 4th at 10:00 am ET
- Wells
Fargo 19th
Annual Healthcare Conference 2024, Boston,
MA, September 5th
- Cantor Global Healthcare
Conference, New York, NY:
Presentation on September 17th at 10:20 am ET
To access the live webcast of BridgeBio’s
presentations, please visit the “Events” page within the Investors
section of the BridgeBio website
at https://investor.bridgebio.com. A replay
of the webcasts will be available on the BridgeBio website for 90
days following the event.
About BridgeBio Pharma, Inc.
BridgeBio Pharma (BridgeBio) is a commercial-stage
biopharmaceutical company founded to discover, create, test and
deliver transformative medicines to treat patients who suffer from
genetic diseases. BridgeBio’s pipeline of development programs
ranges from early science to advanced clinical trials. BridgeBio
was founded in 2015, and its team of experienced drug discoverers,
developers and innovators are committed to applying advances in
genetic medicine to help patients as quickly as possible. For more
information visit bridgebio.com and
follow us
on LinkedIn, Twitter and Facebook.
BridgeBio Contact:Vikram
Balicontact@bridgebio.com(650)-789-8220
BridgeBio Pharma (NASDAQ:BBIO)
Gráfica de Acción Histórica
De Sep 2024 a Oct 2024
BridgeBio Pharma (NASDAQ:BBIO)
Gráfica de Acción Histórica
De Oct 2023 a Oct 2024